Poniard Pharmaceuticals, Inc. (PARD) Stock Price & Analysis

Poniard Pharmaceuticals, Inc. (PARD) Healthcare & Pipeline Overview

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing platinum-based cancer treatments. Its lead product candidate, Picoplatin, has advanced through pivotal Phase III trials for small cell lung cancer and Phase II studies for colorectal and prostate cancers, alongside a Phase I oral formulation, aiming to address critical unmet needs in oncology.

What Is the Investment Thesis for PARD?

Poniard Pharmaceuticals, Inc. presents a research-stage profile centered on its lead candidate, Picoplatin, a platinum-based therapy for various cancers. The company's strategic value proposition is derived from the advanced clinical development of Picoplatin, notably its pivotal Phase III SPEAR trial for second-line small cell lung cancer, alongside Phase II studies for metastatic colorectal and hormone-refractory prostate cancers. These completed trials represent significant milestones in de-risking the therapeutic candidate, providing a foundation for potential future regulatory submissions and market entry. The exploration of an oral formulation in Phase I also indicates a commitment to expanding Picoplatin's utility and patient accessibility. With a market capitalization of $0.00B and a small team of 7 employees, Poniard operates as a highly focused entity, concentrating its resources on the advancement of this singular asset. The company's long operational history, founded in 1984, underscores its enduring dedication to biopharmaceutical development. The potential for Picoplatin to address multiple oncology indications, if successful, could unlock significant value within the substantial global cancer therapeutics market. Future value drivers would hinge on positive clinical outcomes, successful regulatory approvals, and strategic partnerships for commercialization.

Based on FMP financials and quantitative analysis

PARD Key Highlights

Market capitalization of $0.00B, reflecting its early-stage development focus and lean operational structure.

• Beta of -36.63, indicating an unusual and potentially highly volatile or thinly traded stock characteristic.
• Does not pay a dividend, consistent with a biopharmaceutical company in the research and development phase.
• Operates with a small team of 7 employees, emphasizing a highly focused and specialized operational model.
• Primary strategic asset is Picoplatin, a platinum-based cancer therapy that has advanced through pivotal Phase III clinical trials.

Who Are PARD's Competitors?

PARD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PARD's Key Strengths?

Dedicated focus on a single, advanced-stage product candidate, Picoplatin, across multiple cancer types.

• Picoplatin has progressed through significant clinical milestones, including a pivotal Phase III trial.
• Long operational history, founded in 1984, indicating experience in biopharmaceutical development.
• Exploration of an oral formulation for Picoplatin, potentially enhancing patient convenience and market appeal.

What Are PARD's Weaknesses?

High dependence on the success of a single product candidate, Picoplatin, for future viability.

• Extremely small team of 7 employees, potentially limiting operational scale and speed.
• Market capitalization of $0.00B, suggesting significant funding challenges and limited financial resources.
• Operates on the OTC market with an 'Unknown' disclosure status, leading to transparency and liquidity issues.

What Are the Key Risks for PARD?

Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.

• Significant financial risk associated with a $0.00B market capitalization and the absence of a dividend, indicating potential funding challenges for ongoing operations and future development.
• Failure to secure regulatory approvals for Picoplatin, even after advanced clinical trials, due to efficacy, safety, or manufacturing concerns.
• High dependence on the success of a single product candidate, Picoplatin, meaning any setbacks could severely impact the company's viability.
• Intense competition within the oncology therapeutics market from established pharmaceutical companies and other biotechs developing novel cancer treatments.
• Operational risks inherent in managing a lean team of 7 employees, potentially limiting the scope and speed of development and commercialization efforts.

What Threats Does PARD Face?

• Risk of clinical trial failures or unfavorable results, which could halt Picoplatin's development.
• Intense competition from larger pharmaceutical companies and other biotechs in the oncology market.
• Significant regulatory hurdles and potential delays in obtaining market approval for Picoplatin.
• Ongoing need for substantial funding to complete development and commercialization, given its current financial profile.
• Risks associated with OTC trading, including low liquidity and limited investor confidence.

What Are PARD's Competitive Advantages?

• Proprietary drug candidate, Picoplatin, a platinum-based therapy with specific targeting potential.
• Advanced clinical trial data, including a pivotal Phase III trial for small cell lung cancer, representing significant development investment.
• Focus on multiple distinct cancer indications, potentially broadening market reach if successful.
• Specialized expertise in platinum-based chemotherapy development.

What Does PARD Do?

Poniard Pharmaceuticals, Inc., founded in 1984 as NeoRx Corporation, has evolved into a biopharmaceutical entity dedicated to the discovery and market introduction of innovative cancer treatments. The company, which rebranded to its current name in September 2006, operates from its headquarters in Seattle, Washington, with a lean team of 7 employees. Its core strategic focus revolves around its flagship product candidate, Picoplatin. Picoplatin is a platinum-based therapeutic agent designed to target and treat a range of aggressive cancer types. These include small cell lung cancer, metastatic colorectal cancer, hormone-refractory prostate cancer, and ovarian cancers, representing significant areas of unmet medical need within oncology. Poniard has systematically advanced Picoplatin through various rigorous clinical development stages. This includes the completion of a pivotal Phase III SPEAR trial, which evaluated Picoplatin for the second-line treatment of patients diagnosed with small cell lung cancer. This advanced stage of clinical investigation signifies a substantial commitment to bringing this therapy to market for a challenging indication. Furthermore, the company has conducted Phase II studies to explore Picoplatin's efficacy as a first-line treatment for metastatic colorectal cancer, a disease with complex treatment paradigms. Concurrently, Phase II trials also investigated its potential in hormone-refractory prostate cancer, another area requiring effective therapeutic options. In addition to intravenous formulations, Poniard has explored alternative delivery methods, evidenced by an early-stage Phase I trial examining an oral formulation of Picoplatin for solid tumors, which could offer enhanced patient convenience and broader applicability. Through these extensive clinical development efforts, Poniard Pharmaceuticals, Inc. aims to establish Picoplatin as a valuable addition to the cancer treatment landscape, leveraging its platinum-based mechanism of action to improve patient outcomes across multiple oncology indications.

What Products and Services Does PARD Offer?

• Develops and aims to commercialize cancer therapeutics.
• Focuses on its lead product candidate, Picoplatin, a platinum-based cancer therapy.
• Targets multiple cancer indications including small cell lung, colorectal, prostate, and ovarian cancers.
• Has conducted a pivotal Phase III SPEAR trial for second-line small cell lung cancer.
• Evaluated Picoplatin in Phase II trials for first-line metastatic colorectal cancer.
• Investigated Picoplatin in Phase II trials for hormone-refractory prostate cancer.
• Explored an oral formulation of Picoplatin in a Phase I study for solid tumors.
• Operates as a biopharmaceutical company from Seattle, Washington.

How Does PARD Make Money?

• Primarily engaged in the research and development of novel cancer treatments.
• Aims to bring its lead product candidate, Picoplatin, through clinical trials to market introduction.
• Potential future revenue generation from the commercialization or licensing of Picoplatin.
• Relies on funding to support extensive clinical development stages for its drug pipeline.

What Industry Does PARD Operate In?

Poniard Pharmaceuticals, Inc. operates within the highly competitive and innovation-driven biotechnology sector, specifically focusing on oncology therapeutics. The cancer treatment market is characterized by continuous research and development, aiming to address diverse and often aggressive disease types. Platinum-based therapies, like Poniard's Picoplatin, represent a foundational class of chemotherapy agents, and ongoing efforts focus on improving their efficacy, safety profile, and delivery methods. Poniard's strategy positions it as a developer of a potentially differentiated platinum compound, targeting indications such as small cell lung, colorectal, prostate, and ovarian cancers, which collectively represent significant patient populations and market opportunities. The industry landscape includes numerous large pharmaceutical companies and smaller biotechs developing novel chemotherapies, targeted therapies, immunotherapies, and combination regimens. Poniard's advancement of Picoplatin through Phase III and Phase II trials places it among companies with late-stage assets, seeking to carve out a niche by offering an alternative or improved treatment option within established therapeutic areas.

Who Are PARD's Key Customers?

• Patients suffering from various cancer types, including small cell lung, colorectal, prostate, and ovarian cancers.
• Oncology specialists and healthcare providers seeking new treatment options for their patients.
• The broader global oncology market, addressing unmet medical needs in cancer therapy.

Poniard Pharmaceuticals, Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 7.1% above estimates on average.

Poniard Pharmaceuticals, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

Company Profile

Poniard Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Seattle, US. The company is led by CEO Robert F. Caspari. PARD has traded publicly since 1988.

12 transactions · 0 purchases, 2 sales, 10 other transactions · 4 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

PARD Financials

PARD Latest News

PARD Analyst Consensus

PARD MoonshotScore

What Investors Ask About Poniard Pharmaceuticals, Inc. (PARD) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources